

# Curriculum Vitae

## Dimitris Kardassis, PhD

Professor of Biochemistry, University of Crete Medical School  
Affiliated faculty member, IMBB-FORTH, Heraklion Greece  
Tel. +30-2810-321889, e-mail: [kardassis@uoc.gr](mailto:kardassis@uoc.gr); [kardassis@imbb.forth.gr](mailto:kardassis@imbb.forth.gr)

### *Undergraduate education*

1981-1985 B. Sc. in Biology, Department of Biology, Aristotelian University of Thessaloniki, Thessaloniki, Greece

### *Graduate education*

1986-1991 Ph.D. in Biochemistry, Department of Biochemistry, Boston University Medical Center, Boston, MA, USA  
PhD supervisor: Prof. Vassilis I. Zannis  
Title of PhD thesis: “Transcriptional regulatory interactions between nuclear factors and DNA sequence elements on the promoter of the human apolipoprotein B gene”

### *Postdoctoral education*

1991-1992 Postdoctoral fellow, Section of Molecular Genetics, Whittaker Cardiovascular Institute, Boston University Medical School, Boston, MA, USA.

### *Academic Positions*

1993-1996 Research Associate, University of Crete Medical School  
1996-1998 Adjunct Assistant Professor of Biochemistry, University of Crete Medical School  
1998- Assistant Professor of Biochemistry, University of Crete Medical School  
1999- Affiliated Faculty Member, Division of Gene Regulation and Epigenetics, Institute of Molecular Biology and Biotechnology, FORTH  
2004-2008 Associate Professor of Biochemistry, University of Crete Medical School  
2009- Professor of Biochemistry, University of Crete Medical School

### *Fellowships*

1981-1985 Fellowship from the Foundation for National Fellowships (IKY)  
1986-1991 Research Assistantship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center  
1991-1992 Postdoctoral Fellowship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center  
1994 EMBO Short Term Fellowship

### *Awards/Distinctions*

1999 Young Investigator Award, European Atherosclerosis Society  
2004- Fellow of the American Heart Association  
2009-2010 Chairman of the Department of Basic Sciences, University of Crete Medical School  
2010-2014 Election as Chair of COST Action BM0904 “HDL: from biological understanding to clinical exploitation”  
2013-2017 Member of the Organizing Committee of the European Lipoprotein Club  
2012- Director of the Graduate Program “The Molecular Basis of Human Diseases” of the University of Crete Medical School

- 2017- Elected member of the Board of Directors of the Hellenic Society of Biochemistry and Molecular Biology
- 2017- Vice-Chair of the Working Group on “Pathophysiology of Atherosclerosis” of the Hellenic Society of Atherosclerosis

### **Teaching duties**

#### **Undegraduate courses**

- 1993- Teaching in the following courses of the Department of Medicine of the University of Crete:
- a) Biochemistry A (2nd semester): 30 hours of lectures (Course Coordinator)
- b) Molecular Medicine (5th semester): 8 hours of lectures and 20 hours of student presentations (Course Coordinator)

#### **Graduate courses**

- a) Graduate courses offered by the Graduate Program in Molecular Biology and Biomedicine (Departments of Medicine and Biology of the University of Crete) (<http://www.imbb.forth.gr/mbb/>)
- 1998-2007
- Coordination of the graduate course “Molecular Biology of the gene”
  - Teaching in the graduate course “Molecular Biology of the cell”
  - Teaching in the graduate course “Multidisciplinary approach to understand and cure human diseases”
  - Coordination of the graduate course “Introduction to Research Methods”
  - Teaching in the graduate course: “Molecular Biology of Cancer”
  - Coordination of the graduate course “Molecular Organization of Life”
  - Teaching in the graduate course “Cellular Organization of Life”
  - Teaching in the graduate course “Organization and processing of biological information”
- b) Graduate courses offered by the Graduate Program “The molecular basis of human diseases” (Department of Medicine of the University of Crete) (<http://www.grad-mbhd-uoc.gr>)

- 2003- Coordinator of the graduate course “Introduction to molecular medicine and basic principles of research methodology”

#### **Reviewer for the following Journals**

PLoS One; European Journal of Pharmacology; Translational Research; Atherosclerosis; Atherosclerosis, Thrombosis and Vascular Biology; Scientific Reports; Journal of Immunological Sciences; Oncogene; Nucleic Acids Research; BBA; Biochemistry-USA; Journal of Biological Chemistry; Circulation Research; Current Medicinal Chemistry; Cancer Management and Research; Archives of Medical Science; Journal of Cellular and Molecular Medicine; Translational Research; American Journal of Physiology-Endocrinology and Metabolism; Peertechz Journal of Biological Research and Development; OncoTargets and Therapy; Journal of Biomedical Research; Arthritis Research & Therapy; Cell and Tissue Research; Cellular Physiology and Biochemistry; Metabolism.

#### **Editor**

“High Density Lipoproteins: From Biological Understanding to Clinical Exploitation” Arnold von Eckardstein and Dimitris Kardassis Editors, Handbook of Experimental Pharmacology Vol. 224 Springer Open, 2015.

#### **Invited presentations**

1. Invited speaker at the International Workshop on HDL and cardiovascular risk: potential for intervention, Biarritz, France June 13<sup>th</sup>, 2012. Title of presentation: *Transcriptional regulation of HDL*.

2. Invited speaker at the EAS Satellite Symposium “High Density Lipoproteins: From basic science to therapeutic advances”, Milano Italy, May 28-29, 2012. Title of presentation: *Mechanisms of ABCA1 gene regulation in the liver*
3. Invited speaker at the 1st Summer School on HDL in Groningen The Netherlands, August 30-September 1, 2012. Title of presentation: *Regulation of HDL metabolism.*
4. Invited speaker at the 1<sup>st</sup> Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2012. Title of presentations. 1) *Transcriptional regulation of genes involved in lipoprotein metabolism*, 2) *The molecular and genetic basis of atherosclerosis*, 3) *HDL: From biological understanding to clinical exploitation*
5. Invited speaker at the 1<sup>st</sup> Postgraduate Symposium in Translational Medicine of WHBA, Ioannina Grece February 22-24, 2013. Title of Presentations: 1) *Lipoprotein and atherosclerosis: evolving concepts*, 2) *High Density Lipoproteins: Metabolism, genetics and regulation.*
6. Invited speaker at the 2nd Summer School on “HDL: Physiology, regulation and therapeutic potential”, Bucharest-Sinaia Romania, August 26-30, 2013. Title of presentation: *Transcriptional regulation of genes involved in HDL metabolism.*
7. Invited speaker at the 81st Congress of the European Atherosclerosis Society, Lyon France Spain, June 2-5, 2013. Title of presentation: *Genetic and non-genetic factors affecting HDL levels and functions.*
8. Invited speaker that the 3rd Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2014. Title of presentations. 1) *Regulation of genes involved in lipoprotein metabolism*, 2) *The molecular and genetic basis of atherosclerosis* 3) *HDL, inflammation and atherosclerosis: Understanding lipoprotein metabolism using animal models.*
9. Invited speaker at the 11th World Hellenic Biomedical Congress - Clinical & Translational Medicine, Itylo Greece, May 21, 2014. Title of presentation: *The role of High Density Lipoprotein Genes in Cardiovascular Disease*
10. Invited speaker at the 3rd Hellenic Forum For Science, Technology & Innovation “MEDICINE FOR THE FUTURE”, Athens Greece, June 29-July 3, 2015. Title of the presentation: *Dyslipidemia, Atherogenesis and Chronic Inflammatory Diseases: Lessons from animal models*

#### **Organisation of international meetings/workshops**

<b>Year</b>	<b>Meeting/Workshop organised</b>
2003	Member of the organizing committee of the EMBO Workshop "Liver gene expression in health and disease" that was held in Lygaria Crete, June 14-18, 2003.
2004	Member of the organizing committee of the "2004 Post-Olympic HDL Workshop" Heraklion Crete, September 1-4, 2004.
2011	Organizer and Chair of the International Workshop on HDL “HDL: from biological understanding to clinical practice”, Athens Greece, January 30, 2011.
2012	Organizer and Chair of the 2 <sup>nd</sup> International Conference of COST BM0904 in Barcelona, Spain, January 26-27, 2012
2012	Co-organizer of the EAS Satellite Symposium “High Density Lipoproteins: From basic science to therapeutic advances”, Milano Italy, May 28-29, 2012.
2012	Organizer and Co-Chair of the Joint COST/NSFA International Workshop “HDL and cardiovascular risk: potential for intervention” Biarritz France, June 13, 2012.
2012	Member of the organizing committee of the 63 <sup>rd</sup> Annual Conference of the Hellenic Society of Biochemistry and Molecular Biology in Heraklion Greece November 9-11, 2012.
2012	Organizer of the 1 <sup>st</sup> Summer School on HDL in Groningen The Netherlands, August 30-

- September 1, 2012
- 2013 Member of the Scientific Board of the 1<sup>st</sup> Postgraduate Symposium in Translational Medicine of WHBA, Ioannin Grece February 22-24, 2013.
- 2013 Co-organizer of the 2<sup>nd</sup> Summer School on “HDL: Physiology, regulation and therapeutic potential”, Bucharest-Sinaia Romania, August 26-30, 2013
- 2014 Member of the Scientific Board of the 3rd Summer School in Biomedical Research & Management of the World Hellenic Biomedical Association (WHBA), Itylo Greece, May 17-25 2014.
- 2013-17 Member of the Organizing Committees of the 36<sup>th</sup>, 37<sup>th</sup>, 38<sup>th</sup>, 39<sup>th</sup> and 40<sup>th</sup> scientific meetings of the European Lipoprotein Club (ELC) in Tutzing, Germany, 2013-2017.
- 2016 Member of the scientific committee of the 84<sup>th</sup> Congress of the European Atherosclerosis Society in Innsbruck, Austria May 29<sup>th</sup> – June 1<sup>st</sup> 2016.
- 2018 Member of the Scientific Committee of the 1<sup>st</sup> Olympiad of Cardiovascular Medicine, International Symposium on Experimental & Clinical Cardiovascular Medicine Athens, May 17<sup>th</sup>-19<sup>th</sup> 2018.

### ***Major contributions to the early careers of excellent researchers***

<b>Name of researcher</b>	<b>Affiliation</b>	<b>Current position</b>
Kalliopi Liadaki	MSc student	Assistant Professor of Biochemistry, University of Thessaly, Greece
Pelagia Vorgia	MSc student	Assistant Professor of Pediatrics, University of Crete, Greece
Costas Drosatos	MSc student,	Assistant Professor, Temple University, USA
Giorgos Koukos	MSc student,	Senior Scientific Researcher, Scientist, Genenotech, USA
Vassiliki Prokova	MSc/PhD student	Brand Manager in Hematology, Abbvie Pharmaceuticals, Greece
Ioanna Mosialou	MSc/PhD student	Assistant Professor, Columbia University, USA
Ioanna Tiniakou	MSc/PhD student	Post-doctoral fellow, NYU, USA
Panagiotis Fotakis	MSc/PhD student	Post-doctoral fellow, Columbia University, USA
Eleftheria Vasilaki	MSc/PhD student	Post-doctoral fellow, Ludwig Institute for Cancer Research, Sweden
Efstathia Thymiakou	MSc/PhD student	Post-doctoral fellow, University of Crete, Greece
Andreas Kateifidis	MSc/PhD student	Sr. Business Operations Analyst, Process Management & Business Analytics, Vertex Pharmaceuticals, USA

### ***Funding***

1999-2002	Program “Human Frontiers (HFSP)” funded by HFSO: Coordinator: Michnick S. Partners: <b>D. Kardassis</b> , A. Moustakas, K Luo. “TGF-β: From the cell surface to the nucleus”, US\$ 120,000
1999-2001	Program “PENED-99” funded by the Greek Ministry of Education: Coordinator: <b>D. Kardassis</b> . "Transcriptional mechanisms and signaling pathways that control the expression of the human apolipoprotein genes“, 147.000 €
2002-2005	Program “PENED-2001” funded by the Greek Ministry of Education: Coordinator: <b>D. Kardassis</b> . “Functions and regulation of the apolipoprotein E gene: Applications to the treatment of cardiovascular Disease and Alzheimer’s Disease”, 235.000 €
2004-2006	“Collaboration between Greece and the USA” program funded by the Greek Ministry of Research and Technology” Coordinator: <b>D. Kardassis (Greece)</b> Partner: V. Zannis (USA). “ A genomics approach to elucidate the role of the lipid transporter ABCA1 in cholesterol homeostasis ”, 60.000 €.

- 2006-2008 Program “PENED-2003” funded by the Greek Ministry of Research and Technology: Coordinator: **D. Kardassis**. “Transcriptional regulation of genes involved in the biogenesis and catabolism of HDL: New approaches to increase plasma HDL levels”, 210.000 €
- 2006-2008 Program “PENED-2003” funded by the Greek Ministry of Research and Technology: Coordinator: C. Sournaras. **Partner: D. Kardassis** “The role of Rho small GTPases in the genomic and non-genomic cellular responses to cytokines”, 180.000 €
- 2005-2007 Program “PYTHAGORAS II” funded by the Greek Ministry of Education: Coordinator: **D. Kardassis**. “Mechanisms of gene regulation by the Transforming Growth Factor  $\beta$  and the Smad proteins”, 50.000 €
- 2006-2007 “Collaboration between Greece and Romania” program funded by the Greek Ministry of Research and Technology” Coordinator: **D. Kardassis (Greece)** Partner: A. Gafencu (Romania). “Regulation of the expresion of the human apolipoprotein E gene in macrophages and the brain: new approaches for the treatment of dyslipidemias and Alzheimer’s Disease ”, 14.000 €.
- 2007-2009 Sixth Framework Program-Health-STREP. Funded by EU. Coordinator: **A. von Eckardstein (Switzerland)** Partners: V. Zannis, **D. Kardassis (Greece)**. “Functional genomics of inborn errors and therapeutic interventions in high density lipoprotein (HDL) metabolism”. Budget for the team: 420.000 €.
- 2011-2014 Program “SYNERGASIA 09” funded by the General Secretariat for Research and Technology of Hellas “Targeted strategies for new therapies of Cardiovascular and Inflammatory Diseases based on the atheroprotective functions of HDL”. **Coordinator: D. Kardassis**. Patners: A. Chroni (Demokritos), D. Boumpas (Ucrete), Abbott Hellas 500.000 €
- 2010-2013 Program “HRAKLEITOS II” funded by the Greek Ministry of Education. **Coordinator: D. Kardassis**. PhD candidate: P. Fotakis. “Proteins that regulated HDL levels and functions”. 45.000 €
- 2010-2014 COST Action BM0904: “HDL- From Biological Understanding to Clinical Exploitation”. Funded by EU/ESF. **Chair: D. Kardassis (Greece)**. Participants from 15 European countries. 100.000 €/year
- 2012-2015 Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Structure/function, regulation and genetic variation of High Density Lipoproteins: Novel biomarkers and therapies for patients with Coronary Artery Disease”. **Coordinator: D. Kardassis**. Total budget: 520.000 €. Budget for the team: 200.000 €.
- 2012-2015 Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Cell cycle variations: comparing the stem cell and cancer cell life cycles”. Coordinator: Z. Lygerou. **Coordinator of the University of Crete team: D. Kardassis**. Total budget: 520.000 Euros. Budget for the team: 160.000 €
- 2012-2014 Cooperation between Greece and Romania in Science and Technology funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. **Coordinator: D. Kardassis (Greece)**. Romanian parner: Prof. M. Simionescu (Bucharest). Title: Prospects fot novel therapies of Cardiovascular Diseases that are based on the transcriptional regulation of the apoE gene. 15.000 €.

- 2014-2016 Research Program ARISTEIA II funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “High Density Lipoproteins in the intersection of diabetes, inflammation and cardiovascular disease”. Coordinator: **D. Kardassis**. Total budget: 210.000 Euros.
- 2013-2017 “RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol”. Funded by EU FP7-HEALTH-2012-INNOVATION-1 program. Integrated Project. Chair: B. Groen (Netherlands). **Partner: D. Kardassis** (Greece) 750.000 €
- 2015-2017 IKY-SIEMENS Research grants: “The role of TGF $\beta$  and small Rho GTPases in carcinogenesis and stem cell differentiation. **Coordinator: D. Kardassis**. 15.500 €

### **Publications**

1. Zannis VI, MM Hussain, M Hadzopoulou-Cladaras, A Kouvatsi, **D Kardassis**, C Cladaras. (1988). Molecular biology of human apolipoprotein B and related diseases. Adv. Exp. Med. Biol. 243:107-121.
2. **Kardassis D**, M Hadzopoulou-Cladaras, D Ramji, R Cortese, VI Zannis, C Cladaras. (1990). Characterization of the promoter elements required for hepatic and intestinal transcription of the human apoB gene: Definition of the binding site of a tissue-specific transcriptional factor. Mol. Cell Biol. 10:2653-2658.
3. **Kardassis D**, VI Zannis, C Cladaras. (1990). Purification and characterization of the nuclear factor BA1: A transcriptional activator of the human apoB gene. J. Biol. Chem. 265:21733-21740.
4. Zannis VI, **D Kardassis**, K Ogami, M Hadzopoulou-Cladaras, C Cladaras. (1991). Transcriptional regulation of the human apolipoprotein genes. Adv. Exp. Med. Biol. 285,1-23.
5. Ogami K, **D Kardassis**, C Cladaras, VI Zannis. (1991). Purification and characterization of a heat stable nuclear factor CIIIB1 involved in the regulation of the human apoCIII gene. J. Biol. Chem. 266:9640-9646.
6. Zannis VI, **D Kardassis**, P Cardot, M Hadzopoulou-Cladaras, EE Zanni, C Cladaras. (1992). Molecular biology of the human apolipoprotein genes: Gene regulation and structure/function relationship. Curr. Opin. Lipid. 3:96-113.
7. **Kardassis D**, VI Zannis, C Cladaras. (1992). Organization of the regulatory elements and nuclear activities participating in the transcriptional activation of the apolipoprotein B gene. J. Biol. Chem. 267:2622-2632.
8. Ldias AA, M Hadzopoulou-Cladaras, **D Kardassis**, P Cardot, J Cheng, VI Zannis, C Cladaras. (1992). Transcriptional regulation of human apolipoprotein genes apoB, apoCIII and apoAII by members of the steroid hormone receptor superfamily: HNF-4, ARP-1, EAR-2, and EAR-3. J. Biol. Chem. 267:15849-15860.
9. Cardot, Chambaz J, **Kardassis D**, Cladaras C and Zannis V. I. (1993) Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription. Biochemistry 32: 9080-9093.
10. **Kardassis D**, Laccotrippe, M., Talianidis, I. and Zannis, V. (1996) Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Hypertension 27: 980-1008.
11. **Kardassis, D.**, Tzamelis, I., Talianidis, I. and Zannis V. (1997) The distal apoC-III regulatory elements F to J act as a general modular enhancer for proximal promoters containing hormone response elements. Arteriosclerosis, Thrombosis & Vascular Biology. 17:222-232.

12. Vorgia P., Zannis V. and **Kardassis D.** (1998) A short proximal promoter and Hepatic Control Region-1 contribute to the tissue-specific expression of the apoC-II gene in vitro. *J. Biol. Chem.* 273:4188-4196.
13. Moustakas, A. and **Kardassis, D.** (1998) Activation of the human p21/WAF1/Cip1 gene promoter in hepatic cells by interactions between Sp1 and Smad family members. *Proc Natl Acad Sci U S A.* 95(12):6733-8.
14. **Kardassis, D.**, Sacharidou, E. and Zannis, V. (1998) Activation of the human apolipoprotein C-II promoter by orphan and ligand-dependent nuclear receptors: The regulatory element CII-C is a functional Thyroid Hormone responsive Element (TRE) *J Biol Chem.* 273(28):17810-6.
15. Hadzopoulou-Cladaras, M., Lavrentiadou, S., Zannis, V. and **Kardassis, D.** (1998) Transactivation of the human apoC-III promoter by Activating Transcription Factor-2 (ATF-2) and repression by members of the c-jun family. *Biochemistry.* 37:14078-87.
16. Lavrentiadou, S., Hadzopoulou-Cladaras, M., **Kardassis, D.** and Zannis, V. (1999) Binding specificity and modulation of the apoC-III promoter activity by heterodimers of ligand-dependent nuclear receptors. *Biochemistry.* 38(3):964-75.
17. Ribeiro A, Pastier D, **Kardassis D**, Chambaz J, Cardot P (1999) Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. *J Biol Chem* 274(3):1216-25.
18. Tsapara A, **Kardassis D**, Moustakas A, Gravanis A, and Stournaras C (1999) Expression and characterization of Cys374 mutated human beta-actin in two different mammalian cell lines: impaired microfilament organization and stability. *FEBS Lett* 455(1-2):117-22.
19. **Kardassis, D**, Papakosta, P, Pardali, K. and Moustakas, A. (1999) c-Jun transactivates the promoter of the human p21/WAF-1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. *J. Biol. Chem.* 274:29572-29581.
20. Pardali, K., Kurisaki, A., Moren A., ten Dijke, P., **Kardassis, D.** and Moustakas, A. (2000) Role of Smad proteins and transcription factor Sp1 in p21/WAF1/Cip1 regulation by Transforming Growth Factor  $\beta$ . *J Biol Chem.* 275(38):29244-56.
21. **Kardassis, D.**, Pardali, K. and Zannis, V. (2000) SMAD proteins transactivate the human apoC-III promoter by interacting physically and functionally with Hepatocyte Nuclear Factor 4. *J. Biol. Chem.* 29;275(52):41405-14.
22. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, **Kardassis D.** (2001) Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. *J Biol Chem.* 276(31):29116-25.
23. Zannis VI, Kan HY, Kritis A, Zanni EE, **Kardassis D.** (2001) Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. *Curr Opin Lipidol* 12(2):181-207.
24. Zannis VI, Kan HY, Kritis A, Zanni E, **Kardassis D.** (2001) Transcriptional regulation of the human apolipoprotein genes. *Front Biosci* 1;6:D456-504.
25. Prokova V, Mosialos G, **Kardassis D.** (2002) Inhibition of transforming growth factor  $\beta$  signaling and Smad-dependent activation of transcription by the latent membrane protein 1 of Epstein Barr Virus. *J Biol Chem.* 277(11):9342-50.
26. **Kardassis, D.**, Flavey E., Tsantili, P., Hadzopoulou-Cladaras, M. and Zannis, V. I. (2002) Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein C-III promoter. *Biochemistry.* 41(4):1217-28.
27. Koutsodontis, G., Moustakas, A. and **Kardassis, D.** (2002) The Role of Sp1 Family Members, the Proximal GC-Rich Motifs, and the Upstream Enhancer Region in the Regulation of the Human Cell Cycle Inhibitor p21(WAF-1/Cip1) Gene Promoter. *Biochemistry.* 41(42):12771-12784.
28. Chou, C., Prokova, V., Shiraishi, K., Valcourt, U., Moustakas, A., Hadzopoulou-Cladaras, M., Zannis, V and **Kardassis D.** (2003) Smad proteins co-activate hepatocyte nuclear factor

- 4 by interacting with multiple domains and enhance hepatic gene transcription. *Mol Biol Cell* 14, 1279-1294.
29. **Kardassis, D.**, Roussou, A., Papacosta, P., Boulias, K., Talianidis, I., and Zannis, V.I. (2003) Synergism between nuclear receptors bound to specific sites of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene induction by bile acids and retinoids. *Biochem J.* 372, 291-304.
  30. Hatzivassiliou, E, Koukos, G., Ribeiro, A., Zannis, V.I. and **Kardassis, D.** (2003) Functional specificity of two hormone response elements present on the human apoA-II promoter that bind RXRa/T3Rb heterodimers for retinoids and thyroids: synergistic interactions between T3Rb and the ubiquitous transcription factor USF2a. *Biochemical J.* 376, 423-31.
  31. Zannis, V., Liu, T., Zanni, E., Kan, H. and **Kardassis, D.** (2003) Regulatory gene mutations affecting apolipoprotein gene expression: functions and regulatory behavior of known genes may guide future pharmacogenomic approaches to therapy. *Clin Chem Lab Med.* 41(4):411-24.
  32. Zannis, V., Chroni, A., Kypreos, K., Kan, HY., Cesar, TB., Zanni, EE. And **Kardassis, D.** (2004) Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. *Curr. Op. Lipid.* 15(2):151-66.
  33. Koutsodontis, G. and **Kardassis, D.** (2004) Inhibition of p53-mediated transcriptional responses by mithramycin A. *Oncogene.* 23, 9190-200.
  34. Koutsodontis G, Vasilaki E, Chou WC, Papakosta, P. and **Kardassis D.** (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. *Biochem J.* 389, 443-55.
  35. Prokova, V, Mavridou, S, Papakosta, P. and **Kardassis, D.** (2005) Characterization of a novel transcriptionally active domain in the transforming growth factor beta-regulated Smad3 protein. *Nucleic Acids Res.* 33, 3708-21.
  36. Nikolaidou-Neokosmidou V, Zannis VI and **Kardassis D.** (2006) Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. *Biochem J.* 398, 439-50.
  37. Drosatos K, Sanoudou D, Kypreos KE, **Kardassis D** and Zannis VI. (2007) A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. *J Biol Chem.* 282, 19556-64.
  38. Koukos G, Chroni A, Duka A, **Kardassis D**, and Zannis VI. (2007) Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. *Biochem J.* 406, 167-74.
  39. Gafencu AV, Robciuc MR, Fuior E, Zannis VI, **Kardassis D**, and Simionescu M. (2007) Inflammatory signaling pathways regulating ApoE gene expression in macrophages. *J Biol Chem.* 282, 21776-85.
  40. Koukos G, Chroni A, Duka A, **Kardassis D**, and Zannis VI. (2007) LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. *Biochemistry.* 46, 10713-21.
  41. Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, **Kardassis D**, Gold SJ, and Zachariou V. RGS9-2 is a negative modulator of mu-opioid receptor function. *J Neurochem.* 103, 617-25.
  42. Thymiakou E, Zannis VI, and **Kardassis D.** (2007) Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. *Biochemistry.* 46, 11473-83.
  43. Prokova V, Mavridou S, Papakosta P, Petratos K, and **Kardassis D.** (2007) Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells. *Biochemistry.* 46, 13775-86.



44. Stavroulaki M, **Kardassis D**, Chatzaki E, Sakellaris G, Lindschau C, Haller H, Tosca A, and Krasagakis K. (2008) Exposure of normal human melanocytes to a tumor promoting phorbol ester reverses growth suppression by transforming growth factor beta. *J Cell Physiol.* 214, 363-70.
45. Minoo P, Hu L, Zhu N, Borok Z, Bellusci S, Groffen J, **Kardassis D**, and Li C. (2008) SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains. *Nucleic Acids Res.* 36, 179-88.
46. Vardouli L, Vasilaki E, Papadimitriou E, **Kardassis D** and Stournaras C (2008) A novel mechanism of TGF $\beta$ -induced actin reorganization mediated by Smad proteins and Rho GTPases. *FEBS J.* 275(16):4074-87.
47. Moschonas A, Kouraki M, Knox P, Thymiakou E, **Kardassis D** and Eliopoulos AG (2008) CD40 ligation induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF- $\kappa$ B and of NF- $\kappa$ B mediated *de novo* synthesis of IRF-1. *Mol Cell Biol.* 28(20):6208-22.
48. Akoumianaki, A., Georgatos, S., **Kardassis, D.** and Theodoropoulos, P. (2009) Nucleocytoplasmic shuttling of soluble tubulin in mammalian cells. *J Cell Sci* 122, 1111-1118.
49. **Kardassis D**, Murphy C, Fotsis T, Moustakas A, Stournaras C. (2009) Control of transforming growth factor beta signal transduction by small GTPases. *FEBS J.* 2009 Jun;276(11):2947-65.
50. Vasilaki, E., Siderakis, M., Papakosta, P., Skourti-Stathaki, K. Mavridou, S. and **Kardassis, D.** (2009) Novel regulation of Smad3 oligomerization and DNA binding by its linker domain. *Biochemistry.* 48(35):8366-78.
51. Bertias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, **Kardassis D**, Mamalaki C, Boumpas DT. (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. *Arthritis Rheum.* 60(1):207-18.
52. Vasilaki E, Papadimitriou E, Tajadura V, Ridley AJ, Stournaras C and **Kardassis D.** (2010) Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways. *FASEB J.* 24(3):891-905.
53. Mavridou S, Venihaki M, Rassouli O, Tsatsanis C, and **Kardassis D.** (2010) Feedback inhibition of human scavenger receptor class B type I gene expression by glucocorticoid in adrenal and ovarian cells. *Endocrinology* 151(7):3214-24.
54. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, **Kardassis D**, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. (2010) Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. *Cancer Res.* 70(12):4949-60.
55. Mosialou I, Zannis VI, and **Kardassis D.** (2010) Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. *J Biol Chem.* 285(40):30719-30.
56. Goulielmos GN, Petraki E, Vassou D, Eliopoulos E, Iliopoulos D, Sidiropoulos P, Aksentijevich I, **Kardassis D**, and Boumpas DT. (2010) The role of the pro-apoptotic protein Siva in the pathogenesis of Familial Mediterranean fever: A structural and functional analysis. *Biochem Biophys Res Commun.* 402(1):141-6
57. Ohnsorg PM, Rohrer L, Perisa D, Kateifides A, Chroni A, **Kardassis D**, Zannis VI, and von Eckardstein A. (2011) Carboxyl Terminus of Apolipoprotein A-I (ApoA-I) Is Necessary for the Transport of Lipid-free ApoA-I but Not Prelipidated ApoA-I Particles through Aortic Endothelial Cells. *J Biol Chem.* 286(10):7744-54

58. Trusca GV, Fuior EV, Florea IC, **Kardassis D**, Simionescu M, and Gafencu AV. (2011) Macrophage-specific upregulation of apolipoprotein E gene expression by STAT1 is achieved via long-range genomic interactions. *J Biol Chem*. [Epub ahead of print]
59. Mosialou I, Krasagakis K, and **Kardassis D**. (2011) Opposite regulation of the human apolipoprotein M gene by oHepatocyte Nuclear Factor 1 and Jun transcription factors. *J Biol Chem*. 13;286(19):17259-69.
60. Stender S, Frikke-Schmidt R, Anestis A, **Kardassis D**, Sethi AA, Nordestgaard BG, Tybjærg-Hansen A. (2011) Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population. *Arterioscler Thromb Vasc Biol*. 31(12):2990-6.
61. Kateifides AK, Gorshkova IN, Duka A, Chroni A, **Kardassis D**, Zannis VI. (2011) Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL. *J Lipid Res*. 52(7):1363-72.
62. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, **Kardassis D**, Nielsen LB, Andersen CB, Køber L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A. (2011) Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. *J Intern Med*. 270(2):136-46
63. Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, **Kardassis D**, Vasilaki E, Huang M, Mitchell JA, Louise H, Prendergast GC, Wilkins MR. (2012) Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia. *Circ Res*. 110(11):1423-34.
64. Schou J, Frikke-Schmidt R, **Kardassis D**, Thymiakou E, Nordestgaard BG, Jensen G, Grande P, Tybjærg-Hansen A. (2012) Genetic variation in ABCG1 and risk of myocardial infarction and ischemic heart disease. *Arterioscler Thromb Vasc Biol*. 32(2):506-15.
65. Papadimitriou E, Vasilaki E, Vorvis C, Iliopoulos D, Moustakas A, **Kardassis D**, Stournaras C. (2012) Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF- $\beta$  and miR-24: role in epithelial-to-mesenchymal transition. *Oncogene*. 31(23):2862-75.
66. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, **Kardassis D**, Zannis VI. (2012) ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. *J Lipid Res*. 54(1):107-15.
67. Trusca VG, Florea IC, **Kardassis D**, Gafencu AV. STAT1 interacts with RXR $\alpha$  to upregulate ApoCII gene expression in macrophages. *PLoS One*. 2012;7(7):e40463.
68. Stagakis I, Bertsiyas G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, **Kardassis D**, Boumpas DT, Sidiropoulos PI. (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. *Arthritis Res Ther*. 14(3):R141.
69. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, **Kardassis D**, Zannis VI. (2013) ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. *J Lipid Res*. 54(1):107-15.
70. Papadakis G, Tsortos A, Kordas A, Tiniakou I, Morou E, Vontas J, **Kardassis D**, Gizeli E. (2013) Acoustic detection of DNA conformation in genetic assays combined with PCR. *Sci Rep*. 3:2033.
71. Dimopoulou DG, Zervou MI, Trachana M, Myrthianou E, Pratsidou-Gertsi P, **Kardassis D**, Garyfallos A, Goulielmos GN. (2013) Investigation of juvenile idiopathic arthritis susceptibility loci: results from a Greek population. *Hum Immunol*. 74(9):1194-8.
72. Costet P, Ehrenborg E, Fisher R, Fielding B, Groen A, **Kardassis D**, Malle E, Mulder M, Niemeier A, Norata GD, Hansen AT, Eckardstein Av. (2013) European lipoprotein club: report of the 35th ELC annual conference. *Atherosclerosis*. 226(2):510-6.
73. Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, **Kardassis D**. (2013) Significance of the hydrophobic residues 225 to 230 of apoA-I for the biogenesis of HDL. *J Lipid Res*. 54(12):3293-302.

74. Fotakis P, Kateifides A, Gkolfinopoulou C, Georgiadou D, Beck M, Grundler K, Chroni A, Stratikos E, **Kardassis D**, Zannis VI. (2013) Role of the hydrophobic and charged residues in the 218 to 226 region of apoA-I in the biogenesis of HDL. *J Lipid Res.* 2013 Dec;54(12):3281-92.
75. Fotakis P, Vezeridis A, Dafnis I, Chroni A, **Kardassis D**, Zannis VI. (2014) apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. *J Lipid Res.* 55(7):1310-1323.
76. Thymiakou E, **Kardassis D**. Novel mechanism of transcriptional repression of the human ATP binding cassette transporter A1 gene in hepatic cells by the winged helix/forkhead box transcription factor A2. *Biochim Biophys Acta.* 1839(6):526-36.
77. Kardassis D, Mosialou I, Kanaki M, Tiniakou I, Thymiakou E. (2014) Metabolism of HDL and its regulation. *Curr Med Chem.* 21(25):2864-80.
78. **Kardassis D**, Gafencu A, Zannis VI, Davalos A. (2015) Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. *Handb Exp Pharmacol.* 224:113-79.
79. Zannis VI, Fotakis P, Koukos G, **Kardassis D**, Ehnholm C, Jauhiainen M, and Chroni A. (2015) HDL biogenesis, remodeling, and catabolism. *Handb Exp Pharmacol.* 224:53-111.
80. Tiniakou I, Drakos E, Sinatkas V, Van Eck M, Zannis VI, Boumpas D, Verginis P, and **Kardassis D**. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. *J Immunol.* 2015 May 15;194(10):4676-87.
81. Fotakis P, Kuivenhoven JA, Dafnis E, **Kardassis D**, and Zannis VI. (2015) The Effect of Natural LCAT Mutations on the Biogenesis of HDL. *Biochemistry.* 54(21):3348-59.
82. Gkouskou KK, Ioannou M, Pavlopoulos GA, Georgila K, Sigano A, Nikolaidis G, Kanellis DC, Moore S, Papadakis KA, **Kardassis D**, Iliopoulos I, McDyer FA, Drakos E, Eliopoulos AG. (2015) Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. *Oncogene.* 35(19):2496-505.
83. Gkolfinopoulou C, Stratikos E, Theofilatos D, **Kardassis D**, Voulgari PV, Drosos AA, and Chroni A. (2015) Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. *J Rheumatol.* 42(9):1652-60.
84. Tiniakou I, Kanaki Z, Georgopoulos S, Chroni A, Van Eck M, Fotakis P, Zannis VI, and **Kardassis D**. (2015) Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. *Atherosclerosis.* 243(1):77-85.
85. Stavri S, Simionescu M, **Kardassis D**, and Gafencu AV. (2015) Krüppel-like factor 4 synergizes with CREB to increase the activity of apolipoprotein E gene promoter in macrophages. *Biochem Biophys Res Commun.* 468(1-2):66-72.
86. Roman C, Fuior EV, Trusca VG, **Kardassis D**, Simionescu M, and Gafencu AV. (2015) Thyroid hormones upregulate apolipoprotein E gene expression in astrocytes. *Biochem Biophys Res Commun.* 468(1-2):190-5.
87. Theofilatos D, Anestis A, Hashimoto K, **Kardassis D**. (2016) Transcriptional regulation of the human Liver X Receptor  $\alpha$  gene by Hepatocyte Nuclear Factor 4 $\alpha$ . *Biochem Biophys Res Commun.* 469(3):573-9.
88. Carthy JM, Stöter M, Bellomo C, Vanlandewijck M, Heldin A, Morén A, **Kardassis D**, Gahman TC, Shiau AK, Bickle M, Zerial M, Heldin CH, Moustakas A. (2016) Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation. *Sci Rep.* 6:29868.
89. Latsoudis H, Mashreghi MF, Grün JR, Chang HD, Stuhlmüller B, Repa A, Gergiannaki I, Kabouraki E, Haeupl T, Radbruch A, Sidiropoulos P, **Kardassis D**, Boumpas DT, Goulielmos GN. (2017) Differential Expression of miR-4520a Associated with Pyrin Mutations Suggesting a Role of Autophagy in Familial Mediterranean Fever (FMF). *J Cell Physiol.* 232(6):1326-1336.

90. Myrthianou E, Zervou MI, Budu-Aggrey A, Eliopoulos E, **Kardassis D**, Boumpas DT, Kougkas N, Barton A, Sidiropoulos P, Goulielmos GN. (2017) Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population. *Scand J Rheumatol.* 46(3):180-186.
91. Kanaki M, **Kardassis D**. (2017) Regulation of the human lipoprotein lipase gene by the forkhead box transcription factor FOXA2/HNF-3 $\beta$  in hepatic cells. *Biochim Biophys Acta.*1860(3):327-336.
92. Trusca VG, Fuior EV, Fenyó IM, **Kardassis D**, Simionescu M, Gafencu AV. (2017) Differential action of glucocorticoids on apolipoprotein E gene expression in macrophages and hepatocytes. *PLoS One.* 2017 Mar 29;12(3):e0174078.
93. Kanaki M, Tiniakou I, Thymiakou E, **Kardassis D**. (2017) Physical and functional interactions between nuclear receptor LXR $\alpha$  and the forkhead box transcription factor FOXA2 regulate the response of the human lipoprotein lipase gene to oxysterols in hepatic cells. *Biochim Biophys Acta.* 1860(8):848-860.
94. Nomikou E, Stournaras C, **Kardassis D**. (2017) Functional analysis of the promoters of the small GTPases RhoA and RhoB in embryonic stem cells. *Biochem Biophys Res Commun.* 491(3):754-759.
95. Bellomo C, Caja L, Fabregat I, Mikulits W, **Kardassis D**, Heldin CH and Moustakas A. (2017) Snail mediates crosstalk between TGF $\beta$  and LXR $\alpha$  in hepatocellular carcinoma. *Cell Death Differ.* 25(5):885-903.
96. Nomikou E, Livitsanou M, Stournaras C, **Kardassis D**. (2018) Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases. *Cell Mol Life Sci.* 75(12):2111-2124
97. Chroni A, and **Kardassis D**. (2018) HDL dysfunction caused by mutations in apoA-I and other genes that are critical for HDL biogenesis and remodeling. *Curr Med Chem.* [Epub ahead of print] PMID: 29532752.
98. Livitsanou M, Vasilaki E, Stournaras C, and **Kardassis D**. (2018) Modulation of TGF $\beta$ /Smad signaling by the small GTPase RhoB. *Cell Signal.* 48:54-63.
99. Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, **Kardassis D**. (2018) HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. *Metabolism.* 87:36-47.
100. Jaeger, A., Saely, C.H., Muendlein, A., Evangelakos, I., Nasias, D., Charizopoulou, N., **Kardassis, D.**, Drexel, H. and von Eckardstein, A. (2018) Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. *Sci. Rep.* 8(1):14274.
101. Morén A, Bellomo C, Tsubakihara Y, **Kardassis D**, Mikulits W, Heldin CH, Moustakas A. (2019) LXR $\alpha$  limits TGF $\beta$ -dependent hepatocellular carcinoma associated fibroblast differentiation. *Oncogenesis.* May 16;8(6):36.
102. Gomes CPC, Ágg B, Andova A, Arslan S, Baker A, Barteková M, Beis D, Betsou F, Wettinger SB, Bugarski B, Condorelli G, Silva GJJ, Danilin S, de Gonzalo-Calvo D, Buil A, Carmo-Fonseca M, Enguita FJ, Felekis K, Ferdinandy P, Gyöngyösi M, Hackl M, Karaduzovic-Hadziabdic K, Hellemans J, Heymans S, Hlavackova M, Hoydal MA, Jankovic A, Jusic A, **Kardassis D**, Kerkelä R, Kuster GM, Lakkisto P, Leszek P, Lustrek M, Maegdefessel L, Martelli F, Novella S, O'Brien T, Papanephytous C, Pedrazzini T, Pinet F, Popescu O, Potočnjak I, Robinson E, Sasson S, Scholz M, Simionescu M, Stoll M, Varga ZV, Vinciguerra M, Xuereb A, Yilmaz MB, Emanuelli C, Devaux Y, on behalf of the EU-CardioRNA COST Action (CA17129). (2019) Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. *Noncoding RNA.* Mar 29;5(2).
103. Trusca VG, Fuior EV, **Kardassis D**, Simionescu M, Gafencu AV. (2019) The Opposite Effect of c-Jun Transcription Factor on Apolipoprotein E Gene Regulation in Hepatocytes and Macrophages. *Int J Mol Sci.* Mar 23;20(6).

104. Nasias D., Evangelakos I., Nidris I., Vassou D., Tarasco E., Lutz T.A. and **Kardassis, D.** (2019) Significant changes in hepatic transcriptome and circulating miRNAs are associated with diet-induced metabolic syndrome in apoE3L.CETP mice. *J. Cell. Physiol.* 2019 Apr 23. doi: 10.1002/jcp.28649. [Epub ahead of print] PubMed PMID:31016757.